ADA and Fanconi anemia: It is possible that even this low transgene marking rate is sufficient in diseases in which gene corrected HSC/progeny have a proliferative advantage over non-transduced cells such as X-linked SCID,18 ADA-SCID,19 and Fanconi anemia.20